Insight on mechanism of hyponatraemia induced by low-dose intravenous pulse cyclophosphamide by 源�吏��솉 et al.
Nephrol Dial Transplant (2010) 25: 3453–3459
Letters and Replies
Advance Access publication 22 July 2010
Insight on mechanism of hyponatraemia induced by
low-dose intravenous pulse cyclophosphamide
Sir,
We read with great interest the recent contribution by Lee et
al. [1]. The authors showed significant clinical data on hy-
ponatraemia induced by low-dose intravenous pulse cyclo-
phosphamide (CYP) [1]. However, they did not reveal
precise and molecular-based mechanisms of hyponatraemia
induced by CYP. We would like to add some possible
mechanisms of CYP-induced hyponatraemia.
Firstly, they speculated that the antidiuretic effect of
cyclophosphamide might be related to increased renal
action of vasopressin by the alkylating metabolites [1],
but did not suggest the possible mechanisms. It was shown
that increased interleukin (IL)-1 and NF-κB [a transcrip-
tional factor of tumour necrosis factor (TNF)-α] by acute
inflammation were significantly associated with reduced
expression of vasopressin receptor (V2R) and aquaporin-2
(AQ2) [2,3]. McBride et al. demonstrated that CYP me-
tabolites (mafosfamide and 4-hydroperoxycyclophospha-
mide) caused the decrease in production of IL-1 and
TNF-α in a dose-dependent manner [4]. Therefore, there
is a possibility that CYP might cause hyponatraemia by
upregulating expression of V2R and AQ2 through suppres-
sion of IL-1 and TNF-α, which are effector molecules in
the downregulation of VR2.
Secondly, they thought that water retention might in-
volve a direct tubular effect of cyclophosphamide metab-
olite on the collecting duct epithelium [1], because it was
demonstrated in a case with established diabetes insipidus
that developed CYP-associated antidiuresis without vaso-
pressin secretion [5]. Regarding this issue, we speculate
that one article by Pouzet et al. might give us an insight
in understanding the possible mechanisms of CYP-in-
duced hyponatraemia [6]. They reported that small
amounts of endogenous AVP, known to be produced by
adrenal and testis in diabetes insipidus rats, could also
contribute to V2 agonism, as well as a possible constitu-
tive activation of the V2 receptors [6]. As we mentioned
above, because the expressions of V2R and AQ2 are in-
creased through suppression of IL-1 and TNF-α by
cyclophosphamide use, small amounts of endogenous
AVP from other sources might have induced water reten-
tion, causing hyponatraemia.
Therefore, further studies are necessary to evaluate the
serial changes of serum sodium, IL-1 and TNF-α levels,
and renal changes of V2R and AQ2 before and after cyclo-
phosphamide therapy. The dose-dependent relationships of
cyclophosphamide with the severity of hyponatraemia
should also be further elucidated in the future.
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Reply
Dear Sir,
We thank Park et al. for their interest in our work [1]. They
postulated two possible mechanisms by which water excre-
tion can be impaired by intravenous cyclophosphamide.
One is the increase in endogenous vasopressin release,
and the other is upregulation of type 2 vasopressin receptor
(V2R) and aquaporin-2 (AQP2). These sound plausible
because cyclophosphamide may affect water homeostasis
either by increasing vasopressin secretion or by potentiat-
ing the effect of endogenous vasopressin at the kidney
[2]. However, the former possibility is not substantial
even though the contribution of vasopressin release from
adrenals and testes is considered. As discussed previously
[1], cyclophosphamide-induced hyponatraemia is not ac-
companied by an elevated plasma vasopressin level and
can occur in a patient with central diabetes insipidus.
The authors specified the possible intrarenal pathway via
which the effect of endogenous vasopressin is potentiated by
cyclophosphamide administration. This possibility is con-
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